Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) EBIT (2016 - 2025)

Historic EBIT for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$52.4 million.

  • Regenxbio's EBIT rose 1557.23% to -$52.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.9 million, marking a year-over-year increase of 3698.98%. This contributed to the annual value of -$233.3 million for FY2024, which is 1297.22% up from last year.
  • Per Regenxbio's latest filing, its EBIT stood at -$52.4 million for Q3 2025, which was up 1557.23% from -$63.3 million recorded in Q2 2025.
  • Regenxbio's EBIT's 5-year high stood at $313.6 million during Q4 2021, with a 5-year trough of -$73.1 million in Q2 2023.
  • Moreover, its 5-year median value for EBIT was -$62.1 million (2024), whereas its average is -$37.3 million.
  • Data for Regenxbio's EBIT shows a peak YoY increase of 68451.1% (in 2021) and a maximum YoY decrease of 51106.73% (in 2021) over the last 5 years.
  • Over the past 5 years, Regenxbio's EBIT (Quarter) stood at $313.6 million in 2021, then plummeted by 118.42% to -$57.8 million in 2022, then fell by 10.61% to -$63.9 million in 2023, then increased by 19.62% to -$51.4 million in 2024, then decreased by 2.03% to -$52.4 million in 2025.
  • Its EBIT was -$52.4 million in Q3 2025, compared to -$63.3 million in Q2 2025 and $12.1 million in Q1 2025.